Karen A Runcie

  • Citations Per Year
Learn More
A series of novel selective phosphodiesterase 4 (PDE4) inhibitors has been developed which displays activity both in vitro and in vivo. These compounds possess good selectivity for the catalytic site of PDE4 over the high affinity Rolipram binding site. In vivo studies demonstrate a reduced propensity to display the emetic side effects which are commonly(More)
In situ oxidation-Wittig methodology has been applied to alpha-hydroxyketones avoiding the problems normally associated with alpha-ketoaldehydes; the procedure is practically simple, and in many cases gives high yields of the product gamma-ketocrotonates; the procedure has also been successfully utilised with ethyl glycolate and glycolaldehyde dimer.
  • 1